The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Relevium Operational Update and Investments for Financial H1 2018
Feb. 23, 2018 09:52AM PST
Longevity InvestingRelevium Technologies (TSXV:RLV) is reporting on an operational update and areas of investment for financial Q2 2018 (October 1, 2017 to December 31, 2017). As quoted in the press release: Aurelio Useche, President and CEO of Relevium stated: “The integration, optimization and scale up of BioGanix since acquisition has gone as expected.” Mr. Useche continued: “Operationally we expected a …
Relevium Technologies (TSXV:RLV) is reporting on an operational update and areas of investment for financial Q2 2018 (October 1, 2017 to December 31, 2017).
As quoted in the press release:
Aurelio Useche, President and CEO of Relevium stated: “The integration, optimization and scale up of BioGanix since acquisition has gone as expected.” Mr. Useche continued: “Operationally we expected a learning curve and expected to overcome all challenges. I think the Operations Team has overcome all challenges and the Company is poised to drive growth in the 2018 calendar year. The e-commerce landscape for nutraceuticals is under constant change and we have been quick on our feet to adapt and maintain sales velocity.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.